Sangamo Therapeutics

DNA helix forming inside a test tube

Pharma

2022 forecast: Cell, gene therapy makers have high hopes

Novartis, BMS and Gilead are among the companies expected to bring in high revenues from their cell and gene therapies in 2022.

Arlene Weintraub Dec 22, 2021 3:00am

Pfizer commits $100M for gene therapies plant in North Carolina

Aug 9, 2017 9:39am